title: Leg ulceration in the sickle cell patient.
abstract: BACKGROUND
  The purpose of this study was to determine cost of care for leg ulcers in sickle cell patients and suggest an improved modality in ulcer care.
  
  
  METHODS
  We performed a retrospective study of a group of sickle cell disease patients with leg ulcers.
  
  
  RESULTS
  Eighteen patients with a leg ulcer (duration: mean, 53.7 months), sickle cell disease, and a mean of 20.7 years of age had various modalities of treatment with the only consistency in healing being a commercial moist-wound dressing.
  
  
  CONCLUSIONS
  There is no consistency in the treatment of the sickle cell patient with a leg ulcer. Treatment with a moist dressing had the best results.
authors.affiliation: St. Luke's Hospital, Bethlehem, PA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Cackovic
authors.forename: C
authors.initials: C
authors.lastname: Chung
authors.forename: L L
authors.initials: LL
authors.lastname: Bolton
authors.forename: M D
authors.initials: MD
authors.lastname: Kerstein
mesh_terms: D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D001120:Arginine / Q000031:analogs & derivatives / Q000627:therapeutic use; D047070:Bandages, Hydrocolloid; D002087:Butyrates / Q000627:therapeutic use; D003102:Colloids; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D017721:Hospital Costs; D006801:Humans; D007871:Leg Ulcer / Q000191:economics / Q000503:physiopathology / Q000628:therapy*; D007902:Length of Stay / Q000191:economics; D008297:Male; D009779:Occlusive Dressings / Q000191:economics*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D012189:Retrospective Studies; D014945:Wound Healing / Q000502:physiology
chemical_list: D002087:Butyrates; D003102:Colloids; D011994:Recombinant Proteins; D004921:Erythropoietin; D001120:Arginine; C033018:arginine butyrate